Primary graft dysfunction (PGD) is a form of acute lung injury that develops within the first 72 hours after lung transplantation. The overall incidence of PGD is estimated to be around 30%, and the 30-day mortality for grade 3 PGD around 36%. PGD is also associated with the development of bronchiolitis obliterans syndrome, a specific form of chronic lung allograft dysfunction. In this article, we will discuss perioperative strategies for PGD prevention as well as possible future avenues for prevention and treatment.
ChristieJDCarbyMBagRCorrisPHertzMWeillD; ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2005;24:1454-1459.
2.
ChristieJDBellamySWareLB, et al. Construct validity of the definition of primary graft dysfunction after lung transplantation. J Heart Lung Transplant. 2010;29:1231-1239.
3.
DiamondJMLeeJCKawutSM, et al; Lung Transplant Outcomes Group. Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med. 2013;187:527-534.
4.
ChristieJDKotloffRMAhyaVN, et al. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med. 2005;171:1312-1316.
5.
PrekkerMEHerringtonCSHertzMIRadosevichDMDahlbergPS.Early trends in PaO(2)/fraction of inspired oxygen ratio predict outcome in lung transplant recipients with severe primary graft dysfunction. Chest. 2007;132:991-997.
6.
PrekkerMENathDSWalkerAR, et al. Validation of the proposed International Society for Heart and Lung Transplantation Grading System for primary graft dysfunction after lung transplantation. J Heart Lung Transplant. 2006;25:371-378.
7.
ChristieJDSagerJSKimmelSE, et al. Impact of primary graft failure on outcomes following lung transplantation. Chest. 2005;127:161-165.
8.
SamanoMNFernandesLMBaranauskasJC, et al. Risk factors and survival impact of primary graft dysfunction after lung transplantation in a single institution. Transplant Proc. 2012;44:2462-2468.
9.
KingRCBinnsOARodriguezF, et al. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg. 2000;69:1681-1685.
10.
ToddJLPalmerSM.Bronchiolitis obliterans syndrome: the final frontier for lung transplantation. Chest. 2011;140:502-508.
11.
DaudSAYusenRDMeyersBF, et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2007;175:507-513.
12.
HuangHJYusenRDMeyersBF, et al. Late primary graft dysfunction after lung transplantation and bronchiolitis obliterans syndrome. Am J Transplant. 2008;8:2454-2462.
13.
DiamondJMArcasoySKennedyCC, et al. Report of the International Society for Heart and Lung Transplantation Working Group on Primary Lung Graft Dysfunction, part II: epidemiology, risk factors, and outcomes—a 2016 Consensus Group Statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2017;36:1104-1113.
14.
SnellGIYusenRDWeillD, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: definition and grading—a 2016 Consensus Group Statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2017;36:1097-1103.
15.
MorrisonMIPitherTLFisherAJ.Pathophysiology and classification of primary graft dysfunction after lung transplantation. J Thorac Dis. 2017;9:4084-4097.
16.
WhitsonBAPrekkerMEHerringtonCS, et al. Primary graft dysfunction and long-term pulmonary function after lung transplantation. J Heart Lung Transplant. 2007;26:1004-1011.
17.
ShahRJDiamondJMCantuE, et al. Latent class analysis identifies distinct phenotypes of primary graft dysfunction after lung transplantation. Chest. 2013;144:616-622.
18.
GelmanAEFisherAJHuangHJ, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part III: mechanisms: a 2016 Consensus Group Statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2017;36:1114-1120.
19.
SuzukiYCantuEChristieJD.Primary graft dysfunction. Semin Respir Crit Care Med. 2013;34:305-319.
20.
BharatAKreiselD.Immunopathogenesis of primary graft dysfunction after lung transplantation. Ann Thorac Surg. 2018;105:671-674.
21.
AltunGTArslantaşMKCinelI.Primary graft dysfunction after lung transplantation. Turk J Anaesthesiol Reanim. 2015;43:418-423.
22.
OtoTExcellLGriffithsAPLevveyBJSnellGI.The implications of pulmonary embolism in a multiorgan donor for subsequent pulmonary, renal, and cardiac transplantation. J Heart Lung Transplant. 2008;27:78-85.
23.
ChristieJDKotloffRMPochettinoA, et al. Clinical risk factors for primary graft failure following lung transplantation. Chest. 2003;124:1232-1241.
24.
WhitsonBANathDSJohnsonAC, et al. Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg. 2006;131:73-80.
25.
KuntzCLHadjiliadisDAhyaVN, et al. Risk factors for early primary graft dysfunction after lung transplantation: a registry study. Clin Transplant. 2009;23:819-830.
26.
BaldwinMRPetersonEREasthausenI, et al. Donor age and early graft failure after lung transplantation: a cohort study. Am J Transplant. 2013;13:2685-2695.
27.
ShigemuraNHoraiTBhamaJK, et al. Lung transplantation with lungs from older donors: recipient and surgical factors affect outcomes. Transplantation. 2014;98:903-908.
28.
LópezIZapataRSoléJ, et al. Early and mid-term results of lung transplantation with donors 60 years and older. Interact Cardiovasc Thorac Surg. 2015;20:47-53.
29.
LoweryEMKuhlmannEAMahoneyELDillingDFKliethermesSAKovacsEJ.Heavy alcohol use in lung donors increases the risk for primary graft dysfunction. Alcohol Clin Exp Res. 2014;38:2853-2861.
30.
BonserRSTaylorRCollettDThomasHLDarkJHNeubergerJ; Cardiothoracic Advisory Group to NHS Blood and Transplant and the Association of Lung Transplant Physicians (UK). Effect of donor smoking on survival after lung transplantation: a cohort study of a prospective registry. Lancet. 2012;380:747-755.
31.
MohitePNZeriouhMSáezDG, et al. Influence of history of cannabis smoking in selected donors on the outcomes of lung transplantation. Eur J Cardiothorac Surg. 2017;51:142-147.
32.
PorteousMKLeeJCLedererDJ, et al. Clinical risk factors and prognostic model for primary graft dysfunction after lung transplantation in patients with pulmonary hypertension. Ann Am Thorac Soc. 2017;14:1514-1522.
33.
EberleinMReedRMBolukbasS, et al; Lung Transplant Outcomes Group. Lung size mismatch and primary graft dysfunction after bilateral lung transplantation. J Heart Lung Transplant. 2015;34:233-240.
34.
Van RaemdonckDHartwigMGHertzMI, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part IV: prevention and treatment: a 2016 Consensus Group Statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2017;36:1121-1136.
35.
CostaJShahLRobbinsH, et al. Use of lung allografts from donation after cardiac death donors: a single-center experience. Ann Thorac Surg. 2018;105:271-278.
36.
InciIHillingerSSchneiterD, et al. Lung transplantation with controlled donation after circulatory death donors. Ann Thorac Cardiovasc Surg. 2018;24:296-302.
37.
VillavicencioMAAxtellALSpencerPJ, et al. Lung transplantation from donation after circulatory death: United States and single-center experience. Ann Thorac Surg. 2018;106:1619-1627.
38.
van SuylenVLuijkBHoekRAS, et al. A multicenter study on long-term outcomes after lung transplantation comparing donation after circulatory death and donation after brain death. Am J Transplant. 2017;17:2679-2686.
39.
KrutsingerDReedRMBlevinsA, et al. Lung transplantation from donation after cardiocirculatory death: a systematic review and meta-analysis. J Heart Lung Transplant. 2015;34:675-684.
40.
Gomez-de-AntonioDCampo-CañaveralJLCrowleyS, et al. Clinical lung transplantation from uncontrolled non–heart-beating donors revisited. J Heart Lung Transplant. 2012;31:349-353.
41.
ThuongMRuizAEvrardP, et al. New classification of donation after circulatory death donors definitions and terminology. Transpl Int. 2016;29:749-759.
BothaPTrivediDWeirCJ, et al. Extended donor criteria in lung transplantation: impact on organ allocation. J Thorac Cardiovasc Surg. 2006;131:1154-1160.
44.
SomersJRuttensDVerledenSE, et al. A decade of extended-criteria lung donors in a single center: was it justified?Transpl Int. 2015;28:170-179.
45.
ZychBSáezDGSabashnikovA, et al. Lung transplantation from donors outside standard acceptability criteria—are they really marginal?Transpl Int. 2014;27:1183-1191.
46.
MorenoPAlvarezASantosF, et al. Extended recipients but not extended donors are associated with poor outcomes following lung transplantation. Eur J Cardiothorac Surg. 2014;45:1040-1047.
47.
VenkateswaranRVPatchellVBWilsonIC, et al. Early donor management increases the retrieval rate of lungs for transplantation. Ann Thorac Surg. 2008;85:278-286.
48.
WareLBLandeckMKoyamaT, et al; California Transplant Donor Network. A randomized trial of the effects of nebulized albuterol on pulmonary edema in brain-dead organ donors. Am J Transplant. 2014;14:621-628.
49.
SalimAMartinMBrownCRheePDemetriadesDBelzbergH.The effect of a protocol of aggressive donor management: implications for the national organ donor shortage. J Trauma. 2006;61:429-435.
50.
SingbartlKMuruganRKaynarAM, et al. Intensivist-led management of brain-dead donors is associated with an increase in organ recovery for transplantation. Am J Transplant. 2011;11:1517-1521.
51.
RaiosCSkinnerEHKeatingJL. Lung management protocols increase the incidence of lung procurement and organ transplantation: a meta-analysis [published online July 17, 2018]. Physiother Theory Pract. doi:10.1080/09593985.2018.1488907
52.
ChangSHKreiselDMarklinGF, et al. Lung focused resuscitation at a specialized donor care facility improves lung procurement rates. Ann Thorac Surg. 2018;105:1531-1536.
53.
MiñambresECollEDuertoJ, et al. Effect of an intensive lung donor-management protocol on lung transplantation outcomes. J Heart Lung Transplant. 2014;33:178-184.
54.
LiuYLiuYSuLJiangSJ.Recipient-related clinical risk factors for primary graft dysfunction after lung transplantation: a systematic review and meta-analysis. PLoS One. 2014;9:e92773.
55.
LedererDJKawutSMWickershamN, et al; Lung Transplant Outcomes Group. Obesity and primary graft dysfunction after lung transplantation: the Lung Transplant Outcomes Group Obesity Study. Am J Respir Crit Care Med. 2011;184:1055-1061.
56.
ShahRJDiamondJMCantuE, et al. Objective estimates improve risk stratification for primary graft dysfunction after lung transplantation. Am J Transplant. 2015;15:2188-2196.
57.
WhitedWMTrivediJRvan BerkelVHFoxMP.Objective donor scoring system for lung transplantation. Ann Thorac Surg. 2019;107:425-429.
58.
OtoTGriffithsAPRosenfeldtFLevveyBJWilliamsTJSnellGI.Early outcomes comparing Perfadex, Euro-Collins, and Papworth solutions in lung transplantation. Ann Thorac Surg. 2006;82:1842-1848.
59.
FischerSMatte-MartynADe PerrotM, et al. Low-potassium dextran preservation solution improves lung function after human lung transplantation. J Thorac Cardiovasc Surg. 2001;121:594-596.
60.
MarascoSFBaileyMMcGladeD, et al. Effect of donor preservation solution and survival in lung transplantation. J Heart Lung Transplant. 2011;30:414-419.
61.
GohrbandtBSimonARWarneckeG, et al. Lung preservation with Perfadex or Celsior in clinical transplantation: a retrospective single-center analysis of outcomes. Transplantation. 2015;99:1933-1939.
62.
HerringtonCSPrekkerMEArringtonAK, et al. A randomized, placebo-controlled trial of aprotinin to reduce primary graft dysfunction following lung transplantation. Clin Transplant. 2011;25:90-96.
63.
BittnerHBRichterMKuntzeT, et al. Aprotinin decreases reperfusion injury and allograft dysfunction in clinical lung transplantation. Eur J Cardiothorac Surg. 2006;29:210-215.
64.
MarascoSFPilcherDOtoT, et al. Aprotinin in lung transplantation is associated with an increased incidence of primary graft dysfunction. Eur J Cardiothorac Surg. 2010;37:420-425.
65.
PaulusPHolfeldJUrbschatA, et al. Prednisolone as preservation additive prevents from ischemia reperfusion injury in a rat model of orthotopic lung transplantation. PLoS One. 2013;8:e73298.
66.
SáenzAAlvarezLSantosM, et al. Beneficial effects of synthetic KL(4) surfactant in experimental lung transplantation. Eur Respir J. 2011;37:925-932.
67.
BoffiniMRicciDBonatoR, et al. Incidence and severity of primary graft dysfunction after lung transplantation using rejected grafts reconditioned with ex vivo lung perfusion. Eur J Cardiothorac Surg. 2014;46:789-793.
68.
LucJGYJacksonKWeinkaufJGFreedDHNagendranJ. Feasibility of lung transplantation from donation after circulatory death donors following portable ex vivo lung perfusion: a pilot study. Transplant Proc. 2017;49:1885-1892.
69.
MoradiellosFJNaranjoJMCórdobaM, et al. Clinical lung transplantation after ex vivo evaluation of uncontrolled non heart-beating donors lungs: initial experience. J Heart Lung Transplant. 2011;30(suppl 4):S38.
70.
TikkanenJMCypelMMachucaTN, et al. Functional outcomes and quality of life after normothermic ex vivo lung perfusion lung transplantation. J Heart Lung Transplant. 2015;34:547-556.
71.
MagouliotisDETasiopoulouVSSvokosAASvokosKAZacharoulisD.Extracorporeal membrane oxygenation versus cardiopulmonary bypass during lung transplantation: a meta-analysis. Gen Thorac Cardiovasc Surg. 2018;66:38-47.
72.
BiscottiMYangJSonettJBacchettaM.Comparison of extracorporeal membrane oxygenation versus cardiopulmonary bypass for lung transplantation. J Thorac Cardiovasc Surg. 2014;148:2410-2415.
73.
BermudezCAShioseAEsperSA, et al. Outcomes of intraoperative venoarterial extracorporeal membrane oxygenation versus cardiopulmonary bypass during lung transplantation. Ann Thorac Surg. 2014;98:1936-1943.
74.
KhalpeyZGilfeatherMSCampPCJrJaklitschMT.Controlled antegrade single lung reperfusion during double lung transplant. Interact Cardiovasc Thorac Surg. 2009;9:932-933.
75.
SchnickelGTRossDJBeyguiR, et al. Modified reperfusion in clinical lung transplantation: the results of 100 consecutive cases. J Thorac Cardiovasc Surg. 2006;131:218-223.
76.
DiamondJMPorteousMKRobertsLJ2nd, et al. The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia. J Heart Lung Transplant. 2016;35:500-507.
77.
BarnesLReedRMParekhKR, et al. Mechanical ventilation for the lung transplant recipient. Curr Pulmonol Rep. 2015;4:88-96.
78.
GeubeMAPerez-ProttoSEMcGrathTL, et al. Increased intraoperative fluid administration is associated with severe primary graft dysfunction after lung transplantation. Anesth Analg. 2016;122:1081-1088.
79.
MorenoIVicenteRMirA, et al. Effects of inhaled nitric oxide on primary graft dysfunction in lung transplantation. Transplant Proc. 2009;41:2210-2212.
80.
BhandarySStoiceaNJosephNWhitsonBEssandohM.Pro: inhaled pulmonary vasodilators should be used routinely in the management of patients undergoing lung transplantation. J Cardiothorac Vasc Anesth. 2017;31:1123-1126.
81.
RyanKMoritaY. Inhaled pulmonary vasodilators and thoracic organ transplantation: does evidence support its use and cost benefit [published online August 27, 2019]. Semin Cardiothorac Vasc Anesth. doi:10.1177/1089253219870636
82.
AmitalAShitritDRavivY, et al. The use of surfactant in lung transplantation. Transplantation. 2008;86:1554-1559.
83.
AmitalAShitritDRavivY, et al. Surfactant as salvage therapy in life threatening primary graft dysfunction in lung transplantation. Eur J Cardiothorac Surg. 2009;35:299-303.
84.
ShahRJBellamySLLocalioAR, et al. A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation. J Heart Lung Transplant. 2012;31:942-949.
85.
DiamondJMMeyerNJFengR, et al; Lung Transplant Outcomes Group. Variation in PTX3 is associated with primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med. 2012;186:546-552.
86.
DiamondJMAkimovaTKaziA, et al; Lung Transplant Outcomes Group. Genetic variation in the prostaglandin E2 pathway is associated with primary graft dysfunction. Am J Respir Crit Care Med. 2014;189:567-575.
87.
CantuESuzukiYDiamondJM, et al; Lung Transplant Outcomes Group. Protein quantitative trait loci analysis identifies genetic variation in the innate immune regulator TOLLIP in post-lung transplant primary graft dysfunction risk. Am J Transplant. 2016;16:833-840.
88.
SomersJRuttensDVerledenSE, et al. Interleukin-17 receptor polymorphism predisposes to primary graft dysfunction after lung transplantation. J Heart Lung Transplant. 2015;34:941-949.
89.
CantuELedererDJMeyerK, et al. Gene set enrichment analysis identifies key innate immune pathways in primary graft dysfunction after lung transplantation. Am J Transplant. 2013;13:1898-1904.
90.
CypelMLiuMRubachaM, et al. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med. 2009;1:4ra9.
91.
MachucaTNCypelMBonatoR, et al. Safety and efficacy of ex vivo donor lung adenoviral IL-10 gene therapy in a large animal lung transplant survival model. Hum Gene Ther. 2017;28:757-765.
92.
Van RaemdonckDNeyrinckACypelMKeshavjeeS. Ex-vivo lung perfusion. Transpl Int. 2015;28:643-656.
93.
ShaverCMWareLB.Primary graft dysfunction: pathophysiology to guide new preventive therapies. Expert Rev Respir Med. 2017;11:119-128.
